Track Phase 2 & Phase 3 clinical trial catalysts driving biotech stock movements
KRAS G12C-positive Tumors • Interim analysis
BioMarin Pharmaceutical approaching key catalyst with interim analysis expected October 2025
Alzheimer's Disease • Primary endpoint
This primary_endpoint represents a key inflection point for Biogen Inc's BIIB080 program. Based on preclinical data and trial design, there is potential for significant stock movement upon data release.
Joint Pain • Fda approval
Laboratorios Silanes S.A. de C.V. is conducting a Phase 3 clinical trial evaluating Celecoxib + Acetaminohen for the treatment of Joint Pain. The primary completion date is October 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
ADHD • Fda approval
S1 Biopharma, Inc. is conducting a Phase 3 clinical trial evaluating Concerta for the treatment of ADHD. The primary completion date is October 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
Neoplasms • Primary endpoint
Phase 3 trial of Alectinib for Neoplasms. Primary completion expected October 2025.
Chronic Spontaneous Urticaria • Fda approval
Taizhou Mabtech Pharmaceutical Co.,Ltd is conducting a Phase 3 clinical trial evaluating CMAB007 for the treatment of Chronic Spontaneous Urticaria. The primary completion date is November 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
KRAS G12C-positive Tumors • Interim analysis
BioMarin Pharmaceutical approaching key catalyst with interim analysis expected October 2025
Malignant Digestive System Neoplasm • Topline data
M.D. Anderson Cancer Center is conducting a Phase 2 clinical trial evaluating MACC-Investigational for the treatment of Malignant Digestive System Neoplasm. The primary completion date is October 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
Chronic Lymphocytic Leukemia (CLL) • Topline data
Dana-Farber Cancer Institute is conducting a Phase 2 clinical trial evaluating Venetoclax for the treatment of Chronic Lymphocytic Leukemia (CLL). The primary completion date is October 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
Metastatic Malignant Neoplasm in the Brain • Topline data
Ohio State University Comprehensive Cancer Center is conducting a Phase 2 clinical trial evaluating OSUC-Investigational for the treatment of Metastatic Malignant Neoplasm in the Brain. The primary completion date is October 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
Single Ventricle Heart Disease • Primary endpoint
Mayo Clinic is conducting a Phase 3 clinical trial evaluating Udenafil for the treatment of Single Ventricle Heart Disease. The primary completion date is October 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
Cadmium Exceeds the Standard • Topline data
Guangdong Jianersheng Pharmaceutical Technology Co., Ltd. is conducting a Phase 2 clinical trial evaluating GMDTC for injection for the treatment of Cadmium Exceeds the Standard. The primary completion date is October 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
Cardiogenic Shock • Topline data
IRCCS San Raffaele is conducting a Phase 2 clinical trial evaluating Cangrelor for the treatment of Cardiogenic Shock. The primary completion date is October 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
Alzheimer's Disease • Primary endpoint
This primary_endpoint represents a key inflection point for Biogen Inc's BIIB080 program. Based on preclinical data and trial design, there is potential for significant stock movement upon data release.
Parkinson Disease • Topline data
FAScinate Therapeutics Inc. is conducting a Phase 2 trial for KM-819 targeting Parkinson Disease. Primary completion expected 2025-10-30.
Anhedonia • Primary endpoint
Region Skane is conducting a Phase 3 clinical trial evaluating Pramipexole for the treatment of Anhedonia. The primary completion date is October 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
Sign up to create watchlists, get alerts, and access detailed catalyst analysis powered by AI.